PMID- 35590121
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2090-5920 (Electronic)
IS  - 1687-157X (Print)
IS  - 1687-157X (Linking)
VI  - 20
IP  - 1
DP  - 2022 May 19
TI  - The potential role of miR-27a and miR-320a in metabolic syndrome in obese 
      Egyptian females.
PG  - 75
LID - 10.1186/s43141-022-00348-x [doi]
LID - 75
AB  - BACKGROUND: Metabolic syndrome (MetS) is a combination of many health 
      complications, such as obesity, high blood pressure, hyperlipidemia, 
      hyperglycemia, and insulin resistance, with an increasing threat of type 2 
      diabetes mellitus (T2DM) and cardiovascular diseases. As the MetS develops, an 
      alteration in the expression of some genes regulated by circulating microRNAs may 
      also develop as a consequence. TaqMan microRNA primers specific for both miR-27a 
      and miR-320a were used to estimate their expression levels in plasma samples 
      collected from two groups: obese females with metabolic syndrome (n = 49) and 
      lean healthy female volunteers (n = 23), to detect if their expression levels 
      were deregulated with MetS. RESULTS: The study results revealed that miR-27a was 
      upregulated in the plasma of MetS group compared to the healthy controls, while 
      miR-320a was downregulated (p </= 0.005). There was a highly significantly positive 
      correlation between miR-27a expression and body mass index (BMI), waist 
      circumference (WC), fasting blood glucose (FBG), insulin resistance (represented 
      as HOMA-IR), and triglycerides (TG), while it showed significantly negative 
      correlation only with HDL-cholesterol (p </= 0.0001). miR-320a showed significantly 
      negative correlation with BMI, WC, waist-hip ratio (WHR), FBG, HOMA-IR, and TG. 
      The expression value of miR-320a was positively correlated with HDL-cholesterol. 
      Area under the curves (AUC) was equal to 1.000 for both microRNAs. CONCLUSION: 
      Our study added more evidence that monitoring changes in expression levels of 
      both miR-27a and miR-320a in MetS patients could help in the evaluation of 
      disease progression, risk, and susceptibility.
CI  - (c) 2022. The Author(s).
FAU - Abd El-Jawad, Amira Mohamed
AU  - Abd El-Jawad AM
AD  - Department of Medical Biochemistry, National Research Centre, Cairo, Egypt. 
      amira.m.gawad@gmail.com.
FAU - Ibrahim, Iman Hassan
AU  - Ibrahim IH
AD  - Department of Biochemistry, Faculty of Pharmacy for Girls, Al-Azhar University, 
      Cairo, Egypt.
FAU - Zaki, Moushira Erfan
AU  - Zaki ME
AD  - Department of Biological Anthropology, National Research Centre, Cairo, Egypt.
FAU - Elias, Tahany Ramzy
AU  - Elias TR
AD  - Department of Medical Biochemistry, National Research Centre, Cairo, Egypt.
FAU - Rasheed, Wafaa Ibrahim
AU  - Rasheed WI
AD  - Department of Medical Biochemistry, National Research Centre, Cairo, Egypt.
FAU - Amr, Khalda Said
AU  - Amr KS
AD  - Department of Medical Molecular Genetics, National Research Centre, Cairo, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20220519
PL  - Netherlands
TA  - J Genet Eng Biotechnol
JT  - Journal, genetic engineering & biotechnology
JID - 101317150
PMC - PMC9120291
OTO - NOTNLM
OT  - Case-control observational study
OT  - Hyperglycemia
OT  - Hyperlipidemia
OT  - Insulin resistance
OT  - Metabolic syndrome
OT  - Obesity
OT  - miR-27a
OT  - miR-320a
COIS- The authors declare that they have no competing interests.
EDAT- 2022/05/20 06:00
MHDA- 2022/05/20 06:01
PMCR- 2022/05/19
CRDT- 2022/05/19 23:40
PHST- 2021/11/17 00:00 [received]
PHST- 2022/04/18 00:00 [accepted]
PHST- 2022/05/19 23:40 [entrez]
PHST- 2022/05/20 06:00 [pubmed]
PHST- 2022/05/20 06:01 [medline]
PHST- 2022/05/19 00:00 [pmc-release]
AID - 10.1186/s43141-022-00348-x [pii]
AID - 348 [pii]
AID - 10.1186/s43141-022-00348-x [doi]
PST - epublish
SO  - J Genet Eng Biotechnol. 2022 May 19;20(1):75. doi: 10.1186/s43141-022-00348-x.